• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    9/8/25 7:55:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    jnj-20250908
    0000200406false00002004062025-09-082025-09-080000200406us-gaap:CommonStockMember2025-09-082025-09-080000200406jnj:A1.150NotesDueNovember2028Member2025-09-082025-09-080000200406jnj:A2.700NotesDueFebruary2029Member2025-09-082025-09-080000200406jnj:A3.20NotesDueNovember2032Member2025-09-082025-09-080000200406jnj:A3.050NotesDueFebruary2033Member2025-09-082025-09-080000200406jnj:A1.650NotesDue2035Member2025-09-082025-09-080000200406jnj:A3.350NotesDueNovember2036Member2025-09-082025-09-080000200406jnj:A3.350NotesDueFebruary2037Member2025-09-082025-09-080000200406jnj:A3.550NotesDueNovember2044Member2025-09-082025-09-080000200406jnj:A3.600NotesDueFebruary2045Member2025-09-082025-09-080000200406jnj:A3.700NotesDueFebruary2055Member2025-09-082025-09-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The
    Securities Exchange Act of 1934
    Date of report (Date of earliest event reported): 
    September 8, 2025
    Johnson & Johnson
    (Exact name of registrant as specified in its charter)
    New Jersey1-321522-1024240
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
    (Address of Principal Executive Offices)
     (Zip Code) 
    Registrant's telephone number, including area code:
    732-524-0400
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
    SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, Par Value $1.00JNJNew York Stock Exchange
    1.150% Notes Due November 2028JNJ28New York Stock Exchange
    2.700% Notes due February 2029JNJ29BNew York Stock Exchange
    3.200% Notes Due June 2032JNJ32New York Stock Exchange
    3.050% Notes due February 2033JNJ33BNew York Stock Exchange
    1.650% Notes Due May 2035JNJ35New York Stock Exchange
    3.350% Notes Due June 2036JNJ36ANew York Stock Exchange
    3.350% Notes due February 2037JNJ37BNew York Stock Exchange
    3.550% Notes Due June 2044JNJ44New York Stock Exchange
    3.600% Notes due February 2045JNJ45New York Stock Exchange
    3.700% Notes due February 2055JNJ55New York Stock Exchange



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual. Mr. Morikis will serve on the Audit Committee and Compensation & Benefits Committee.
    As a non-employee director of the Company, Mr. Morikis will receive compensation as described in the Director Compensation section of the Company’s 2025 Proxy Statement.
    Mr. Morikis served as the Executive Chairman, President and Chief Executive Officer of The Sherwin-Williams Company from 2016 to 2024. He joined Sherwin-Williams in 1984 as a management trainee in the Paint Stores Group. Over the next four decades, he advanced through key leadership roles, including Division President and Group President. From 2006 to 2016, Mr. Morikis served as President and Chief Operating Officer.
    The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.


    Item 9.01 Financial statements and exhibits
    (d)    Exhibits.
    Exhibit No.Description of Exhibit
    99.1
    Press Release dated September 8, 2025
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.



    Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: September 8, 2025
    JOHNSON & JOHNSON
    (Registrant)
    By:
    /s/ Marc Larkins
    Marc Larkins
    Secretary

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    7/23/2025Hold → Buy
    Erste Group
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Erste Group

    Erste Group upgraded Johnson & Johnson from Hold to Buy

    7/23/25 8:55:43 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

    5/13/25 8:56:13 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on Johnson & Johnson with a new price target

    BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

    12/10/24 8:28:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    SEC Filings

    View All

    Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    9/8/25 7:55:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    9/4/25 2:37:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form N-PX filed by Johnson & Johnson

    N-PX - JOHNSON & JOHNSON (0000200406) (Filer)

    8/26/25 4:27:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

    9/3/25 4:29:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

    7/16/25 6:25:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

    2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

    7/16/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 56,471 shares at a strike of $101.87 and sold $10,040,883 worth of shares (56,471 units at $177.81) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/5/25 6:00:47 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP, General Counsel Forminard Elizabeth exercised 11,521 shares at a strike of $115.67 and covered exercise/tax liability with 9,570 shares, increasing direct ownership by 18% to 12,853 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/3/25 5:13:57 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Duato Joaquin exercised 125,824 shares at a strike of $101.87 and sold $22,548,655 worth of shares (125,824 units at $179.21) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    8/25/25 7:12:16 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

    Johnson & Johnson (NYSE:JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250908878054/en/ Media contact: [email protected] Investor contact: [email protected]

    9/8/25 4:25:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

    Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RARITAN, N.J., Sept. 7, 2025 /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced The New England Journal of Medicine (NEJM) published results from the Phase 3 MARIPOSA study, which showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival (OS) improvement for patients with previously

    9/7/25 3:22:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

    WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

    3/25/25 1:11:06 PM ET
    $JNJ
    $TVGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)